

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of KITAMURA et al

Art Unit 1651

Application No 09/380,372

Conf No 2531

Examiner L Lankford, Jr

Filed September 1, 1999

Washington, D C

For NOVEL CELL LINES AND SCREENING METHODS

Atty's Docket KITAMURA=1

Date March 20 2003

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D C 20231

BY HANDCARRY

Sir

Transmitted herewith is a ☐ Amendment ☒ Supplemental Response
in the above-identified application

☐ Small Entity Status Applicant(s) claim small entity status See 37 C F R §1.27

☒ No additional fee is required

☐ The fee has been calculated as shown below

RECEIVED

MAR 24 2003

TECH CENTER 1600/2900

	(Col 1)		(Col 2)	(Col 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP CLAIM				

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	

OR

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	

OR

- * If the entry in Col 1 is less than the entry in Col 2, write "0" in Col 3
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
- ☐ Second - \$ 200.00
- ☐ Third - \$ 460.00
- ☐ Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
- ☐ Second - \$ 400.00
- ☐ Third - \$ 920.00
- ☐ Fourth - \$ 1440.00

Month After Time Period Set

☐ Less fees (\$) already paid for ___ month(s) extension of time on _____

☐ Please charge my Deposit Account No 02-4035 in the amount of \$ _____

☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____

☐ A check in the amount of \$ _____ is attached (check no)

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P L L C

Attorneys for Applicant(s)

By 

Allen C. Yun
Registration No 37,971

Facsimile (202) 737-3528
Telephone (202) 628-5197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1651
)	
Hidetomo KITAMURA)	Examiner: L. Lankford, Jr.
)	
Appln. No.: 09/380,372)	Washington, D.C.
)	
Filed: September 1, 1999)	March 20, 2003
)	
For: NOVEL CELL LINES AND)	Atty. Docket: KITAMURA=1
SCREENING METHODS...)	
)	
Confirmation No.: 2531)	BY HANDCARRY

RECEIVED

MAR 24 2003

ENTER 1600/2900

SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Supplemental to the amendment filed March 10, 2003, with the RCE, on which applicants continue to primarily rely, attached hereto for the examiner's consideration is a second declaration executed by the inventor Hidetomo KITAMURA, that is mentioned in the amendment filed March 10, 2003, and that clearly shows the difference between the RCJ 3.1 fetal cells of Grigoriadis, which requires the presence of dexamethasone for differentiation to adipocytes and chondrocytes, and the cell line derived from a normal adult animal (as claimed in the present invention), which does not require the presence of dexamethasone to differentiate into adipocytes and chondrocytes.

In re Application No.: 09/380,372
Confirmation No.: 2531

Favorable consideration is respectfully solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Allen C. Yun
Registration No. 37,971

ACY:pp
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

1. This document is not to be used for any purpose other than that for which it was prepared.